Josep Llorens net worth and biography

Josep Llorens Biography and Net Worth

EVP of Haemonetics
Josep Llorens was named Executive Vice President, Global Manufacturing and Supply Chain in 2021, and is responsible for expanding manufacturing capacity, upscaling strategic sourcing, driving greater throughput and improving product quality. He joined Haemonetics as Senior Vice President, Global Manufacturing and Supply Chain in August 2018. Mr. Llorens brings over 30 years of experience in transforming supply chain, logistics and manufacturing operations to increase quality, improve customer satisfaction and reduce costs. Prior to joining Haemonetics, he was Senior Vice President, Industrial Strategy and Advanced Manufacturing Engineering Leader for Philips Healthcare Diagnostic Imaging. Before that position, he held various Operations and Supply Chain roles within the Philips healthcare business, delivering supply chain and operations optimization in Diagnostics and Treatment, Patient Monitoring and Cardiac Care businesses and leading global teams focused on continuous improvement. Mr. Llorens holds a bachelor's degree in Business Administration from University of Barcelona and a master's degree in Telecommunications Engineering from the Polytechnic University of Catalonia in Barcelona. He also received an Executive Certificate in Technology, Operations and Value Chain Management from the MIT Sloan School of Management.

What is Josep Llorens' net worth?

The estimated net worth of Josep Llorens is at least $1.49 million as of May 19th, 2022. Mr. Llorens owns 17,335 shares of Haemonetics stock worth more than $1,488,383 as of December 1st. This net worth evaluation does not reflect any other assets that Mr. Llorens may own. Additionally, Mr. Llorens receives a salary of $718,760.00 as EVP at Haemonetics. Learn More about Josep Llorens' net worth.

How old is Josep Llorens?

Mr. Llorens is currently 59 years old. There are 5 older executives and no younger executives at Haemonetics. Learn More on Josep Llorens' age.

What is Josep Llorens' salary?

As the EVP of Haemonetics Co., Mr. Llorens earned a total compensation package of $2,027,855.00 in 2022. Mr. Llorens earned a salary of $440,794.00, stock awards of $1,109,106.00, options awards of $199,990.00, non-equity compensation of $255,645.00, and other compensation of $22,320.00.There are 2 executives that earn more than Mr. Llorens. The highest earning executive at Haemonetics is Mr. Christopher A. Simon, CEO, Pres & Director, who commands a salary of $1,880,000.00 per year. Learn More on Josep Llorens' salary.

How do I contact Josep Llorens?

The corporate mailing address for Mr. Llorens and other Haemonetics executives is 125 Summer Street, Boston MA, 02110. Haemonetics can also be reached via phone at (781) 848-7100 and via email at [email protected] Learn More on Josep Llorens' contact information.

Has Josep Llorens been buying or selling shares of Haemonetics?

Josep Llorens has not been actively trading shares of Haemonetics during the last quarter. Most recently, Josep Llorens sold 1,418 shares of the business's stock in a transaction on Thursday, May 19th. The shares were sold at an average price of $59.10, for a transaction totalling $83,803.80. Following the completion of the sale, the executive vice president now directly owns 17,335 shares of the company's stock, valued at $1,024,498.50. Learn More on Josep Llorens' trading history.

Who are Haemonetics' active insiders?

Haemonetics' insider roster includes Michelle Basil (EVP), William Burke (CFO), Dan Goldstein (VP), Mark Kroll (Director), Anila Lingamneni (EVP), Josep Llorens (EVP), Richard Meelia (Director), Laurie Miller (SVP), Jacqueline Scanlan (SVP), Christopher Simon (CEO), and Stewart Strong (Insider). Learn More on Haemonetics' active insiders.

Are insiders buying or selling shares of Haemonetics?

During the last twelve months, insiders at the medical instruments supplier sold shares 22 times. They sold a total of 62,013 shares worth more than $4,650,299.35. The most recent insider tranaction occured on October, 24th when insider Stewart W Strong sold 75 shares worth more than $6,029.25. Insiders at Haemonetics own 1.7 % of the company. Learn More about insider trades at Haemonetics.

Information on this page was last updated on 10/24/2022.

Josep Llorens Insider Trading History at Haemonetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/19/2022Sell1,418$59.10$83,803.8017,335View SEC Filing Icon  
5/16/2022Sell107$56.10$6,002.7014,413View SEC Filing Icon  
9/7/2021Sell100$64.61$6,461.00View SEC Filing Icon  
5/19/2021Sell125$55.19$6,898.75View SEC Filing Icon  
9/8/2020Sell101$88.71$8,959.71View SEC Filing Icon  
9/5/2019Sell101$129.94$13,123.94View SEC Filing Icon  
See Full Table

Josep Llorens Buying and Selling Activity at Haemonetics

This chart shows Josep Llorens's buying and selling at Haemonetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Haemonetics Company Overview

Haemonetics logo
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $85.86
Low: $84.95
High: $86.50

50 Day Range

MA: $79.32
Low: $72.05
High: $85.31

2 Week Range

Now: $85.86
Low: $43.50
High: $86.48

Volume

2,372 shs

Average Volume

471,650 shs

Market Capitalization

$4.35 billion

P/E Ratio

51.72

Dividend Yield

N/A

Beta

0.4
Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
See This Special Report to Get the Full Story